Annual report pursuant to Section 13 and 15(d)

Licenses Acquired (Tables)

v3.21.1
Licenses Acquired (Tables)
12 Months Ended
Dec. 31, 2020
Licenses Acquired  
Schedule of Research and Development-Licenses

For the years ended December 31, 2020 and 2019, the Company’s research and development-licenses acquired are comprised of the following:

​

​

​

​

​

​

​

​

​

​

For the Year Ended

​

​

​

December 31, 

($ in thousands)

    

2020

    

2019

Partner companies:

 

​

  

 

​

  

Avenue

​

$

—

​

$

1,000

Aevitas

​

​

62

​

​

—

Baergic

​

 

11

​

 

3,290

Cellvation

​

 

1

​

 

—

Helocyte

​

​

—

​

​

450

Mustang

​

​

2,489

​

​

1,350

Oncogenuity

​

​

271

​

​

—

Total

​

$

2,834

​

$

6,090

Schedule of Research and Development for Licenses Acquired

For the years ended December 31, 2020 and 2019 Mustang recorded the following expense in research and development – licenses acquired:

​

​

​

​

​

​

​

​

​

​

For the Year Ended December 31, 

($ in thousands)

    

2020

    

2019

City of Hope National Medical Center

​

​

​

​

​

​

CD123 (MB-102)3

​

$

334

​

$

250

IL13Rα2 (MB-101) 3

​

​

334

​

​

—

HER2 (MB-103)1

​

​

500

​

​

—

CS1 (MB-104)

​

​

200

​

​

200

PSCA (MB-105)3

​

 

200

​

 

200

Spacer

​

​

334

​

​

—

Fred Hutch - CD20 (MB-106)2

​

​

300

​

​

—

Nationwide Children’s Hospital - C134 (MB-108)

​

​

—

​

​

200

CSL Behring (Calimmune)

​

​

170

​

​

200

UCLA

​

​

—

​

​

300

SIRION LentiBOOSTTM

​

​

117

​

​

—

Total

​

$

2,489

​

$

1,350